Mersana Therapeutics (MRSN)
(Real Time Quote from BATS)
$2.16 USD
-0.06 (-2.70%)
Updated Jun 14, 2024 10:08 AM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Brokerage Reports
Mersana Therapeutics, Inc. [MRSN]
Reports for Purchase
Showing records 101 - 120 ( 199 total )
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Horses for Courses; A Preclinical Overview of the NaPi2b Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-1536 Activity Exceeds Expectations; Target Raised to $26
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
XMT-1536 Expansion Impresses: Broad, Deep and Deepening Responses in PROC
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
One Becomes Two, 1592 Joins 1536 in the Clinic
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ASCO Beckons; But the 2H20 Update Likely More Important
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financials; Interim XMT-1536 Expansion Data Coming Soon at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of April 20 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
COVID-19 Impact on Coverage Universe: Week of March 30 Update
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Mersana Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Dose Escalation; Next Up Expansion Data and Registration Study
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D